The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.
Sylvia Jablonski, Defiance ETF co-founder, joins 'Power Lunch' to discuss stock plays for three stocks.
The Wall Street Journal reported that Starboard Value has taken a "sizeable" stake in Kenvue (KVUE) with hopes of matching the company's stock price to competitors. Despite having Tylenol and Band-Aid as part of its brand portfolio, George Tsilis looks at the headwinds facing Kenvue's growth.
Kenvue Inc (NYSE:KVUE) shares moved more than 6% higher on reports activist investor Starboard Value has taken a stake in the consumer goods company and is eyeing changes. A person familiar with the matter told the Wall Street Journal that Starboard's stake in the Tylenol-maker is “sizeable.
Shares of Kenvue (KVUE) took off Monday morning on indications activist investor Starboard Value has taken a large stake in the consumer health products maker.
Starboard Value has amassed a significant stake in Kenvue, which spun out of Johnson & Johnson in mid-2023, according to people familiar with the matter. Starboard's Jeff Smith is expected to detail the position further at 13D Monitor's Active-Passive Investor Summit on Tuesday.
Tylenol, Listerine and Band-Aid maker Kenvue has attracted the activist investor, according to a report.
Activist investor Starboard Value has taken a sizeable stake in Kenvue, the maker of Tylenol and Listerine, and is seeking changes, according to reports Sunday night.
Activist investor Starboard Value has a stake in Kenvue , which makes Listerine and Tylenol, two sources familiar with the matter told Reuters on Sunday.
Starboard wants Kenvue, which was spun out of Johnson & Johnson last year and has a market value of over $40 billion, to make changes to boost its share price.
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.